Induction of haem oxygenase-1 by nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth by Doi, K et al.
Expression of different isoforms of nitric oxide (NO)3 synthase
(NOS) has been documented in various tumour cell lines and solid
tumours (Buttery et al, 1993; Bastian et al, 1994; Thomsen et al,
1994; Cobbs et al, 1995). Our previous experiments indicate that
enhanced vascular permeability in solid tumour is mediated by
at least three factors: NO, bradykinin and prostaglandins
(Matsumura et al, 1988; Wu et al, 1998; Maeda et al, 1994). NO
production by experimental tumours in mice has been implicated
in maintenance of tumour blood flow in the neovasculature, and
blockade of NO with Nw-nitro-L-arginine has been shown to
reduce blood flow in the tumour-associated neovasculature
(Andrade et al, 1992; Tozer et al, 1995, 1997).
Among three types of NOS, the inducible isoform (iNOS)
produces a much larger amount of NO for a longer time than do
the other two constitutive enzymes, i.e. neuronal NOS and
endothelial NOS (Stuehr and Griffith, 1992; Moncada and Higgs,
1993). We recently suggested that NO produced in excess in the
local area of the solid tumour seems to sustain rapid tumour
growth in an experimental solid tumour (Doi et al, 1996). It has
been reported, however, that a particularly high output of NO from
iNOS is potentially cytotoxic for various tumour cells (Hibbs et al,
1988; Bastian et al, 1994; Lepoivre et al, 1994). The biological
effect of NO in tumour biology is thus still unsettled because
of previous inconsistent results, i.e. suppressing effects and
promoting effects on tumour growth. These contradictory effects
of NO may be explained by a putative protective mechanism in the
tumour cells against cytotoxicity of excess NO.
In this respect, of considerable interest is a unique biological
function of haem oxygenase (HO), originally involved in disinte-
gration of haem compounds in iron metabolism (Tenhunen et al,
1968). HO degrades haem to release carbon monoxide (CO), iron
and biliverdin (Maines, 1997). Two isoforms of HO, i.e. HO-1 and
HO-2, are known to exist in eukaryotic systems (Maines and
Kappas, 1974). HO-1 is induced by various stimuli, such as pro-
inflammatory cytokines and heavy metals (Shibahara et al, 1985;
Maines, 1997; Yet et al, 1997). Induction of HO-1 has been
suggested to provide an important protective response of cells
against oxidative damage, because HO-1 induction may decrease
the cellular haem level (pro-oxidant) and elevate the level of
bilirubin (antioxidant), which is derived from biliverdin and shows
a potent scavenging action against reactive oxygen species
(Maines, 1997; Kim et al, 1995a, 1995b). In addition, it is
proposed that CO, a product of HO, functions as a gaseous signal
transduction molecule in a similar manner to that of NO
(Suematsu et al, 1995; Maines, 1997; Prabhakar et al, 1997). It is
of interest that HO has been implicated in tumour growth (Lee and
Ho, 1994; Hara et al, 1996; Goldman et al, 1996; Takahashi et al,
1996), although details of this mechanism remain unclear.
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iNOS in rat AH136B solid tumours.
MATERIALS AND METHODS
Animals and implantation of AH136B tumour
Donryu rats, weighing from 160 to 180 g, were obtained from a
commercial supplier (SLC, Inc., Shizuoka, Japan). They were
handled according to the guidelines of the Experimental Animal
Center of Kumamoto University.
AH136B tumour (hepatoma) cells were cultured serially in
ascitic fluid in rats as described previously (Doi et al, 1996). The
cells were implanted subcutaneously (s.c.) in a dorsal site of the
foot of Donryu rats with an inoculum size of 1 ´ 107 cells per
injection site. Tumours were allowed to grow and usually reached
15–20 mm in diameter for 16 days.
Electron spin resonance spectroscopy for analysis of
NO production in AH136B solid tumours
Overproduction of NO was examined with the solid tumour
obtained 16 days after the tumour cell inoculation by using elec-
tron spin resonance (ESR) spectroscopy according to a previously
described method (Doi et al, 1996; Setoguchi et al, 1996;
Yoshimura et al, 1996). Briefly, a complex of N-(dithiocarboxy)-
sarcosine (DTCS, 180 mg kg–1; Dojindo Laboratories, Kumamoto,
Japan) with FeSO4.7H2O (40 mg kg–1), which is soluble in water,
was injected s.c. ESR was performed 30 min after the administra-
tion of the iron complex, with the tumour obtained as described
below.
The solid tumours obtained with the rats under sodium pento-
barbital anaesthesia were transferred to quartz sample tubes (5 mm
in diameter). The samples were immediately frozen in liquid
nitrogen and then subjected to ESR by using an X-band ESR spec-
trometer (Bruker 380E) at 110K. Unless otherwise specified, the
conditions for ESR measurement were microwave frequency,
9.39 GHz; microwave power, 4 mW; modulation frequency,
100 kHz; and modulation amplitude, 0.5 mT. The magnetic field
was calibrated by using TCNQ-Li salt (g = 2.00252).
Simultaneously, to test the effect of NOS inhibitors on the
formation of NO in the solid tumour, ESR was performed by using
a DTCS-Fe2+ complex 1 h after intraperitoneal (i.p.) injection of
Nw-nitro-L-arginine methyl ester (L-NAME; Sigma Chemical, St
Louis, MO, USA) at 50 mg kg–1 or S-methylisothiourea sulphate
(SMT; Wako Pure Chemical Co., Ltd, Osaka, Japan) at 50 mg kg–1.
Expression and localization of iNOS in AH136B solid
tumours
We previously showed that iNOS mRNA expression is highly
elevated in AH136B solid tumours implanted and grown in rats
(Doi et al, 1996). The localization of iNOS expression was further
examined by an immunohistochemical study using a specific
antibody for rat iNOS according to our previous method
(Setoguchi et al, 1996). Briefly, solid tumour tissue was excised
on day 16 after tumour implantation and fixed with 2%
periodate–lysine–paraformaldehyde for 6 h. The tissue was then
embedded in tissue-embedding medium and frozen in liquid
nitrogen, followed by preparation of 6-mm-thick sections by use
of a cryostat. After inhibition of endogenous peroxidase activity,
the specimens were incubated with an anti-rat iNOS polyclonal
antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA)
for 1 h at room temperature. After the samples were washed with
0.01 M phosphate-buffered 0.15 M saline (PBS, pH 7.4), they
were incubated for 1 h with a sheep antimouse immunoglobulin
[F(ab¢)2] conjugated with peroxidase diluted 1:100. Tissue-bound
peroxidase activity was visualized using 3,3¢-diaminobenzidine as
a substrate; haematoxylin was used for nuclear staining.
In addition, tissue sections were stained immunohistochemi-
cally with a specific antibody against exudate monocyte-derived
macrophages (TRPM-3) (Takeya et al, 1987). As the control,
sections were incubated with non-immunized mouse serum or
PBS instead of primary antibody, after which they were processed
in the manner just described.
Expression and localization of HO-1 in AH136B solid
tumours
First, expression of HO-1 mRNA was analysed by Northern
blotting. Total RNA was extracted from the tumour tissue obtained
at 16 days after tumour inoculation by using the guanidine
thiocyanate lysis method with TrizolTM reagent (GibcoBRL,
Gaithersburg, MD, USA). Each RNA sample (20 mg) underwent
electrophoresis on agarose gel and was transferred to the
HybondTM-N+ nylon membrane, followed by hybridization of a
DNA probe for rat HO-1 mRNA as described previously
(Setoguchi et al, 1996; Akaike et al, 1997). The DNA probe was
radiolabelled by the random primer technique using [a-32P]-dCTP
and the Megaprime labelling systemTM (Amersham International
plc, Buck, UK). An HO-1 cDNA fragment of 882 bp was used for
hybridization as reported previously (Takeda et al, 1994), and a
cDNA fragment for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as the control-gene expression (Akaike et al,
1997).
Western blot analysis for HO-1 protein was also performed by
using a specific polyclonal anti-rat HO-1 antibody (Stress-
Gen Biotechnologies, Victoria, Canada). Tumour tissue obtained
16 days after tumour implantation was homogenized, by use
of a Polytron homogenizer (Kinematica GmbH, Luzerne,
Switzerland), in PBS (pH 7.4) containing 1 mM ethylenediamine
tetraacetic acid (EDTA) and 1 mM phenylmethylsulphonyl
fluoride (PMSF).
The microsome fraction was obtained by ultracentrifugation at
105 000 g for 1 h at 4°C. The microsome preparation was then
solubilized by adding sodium dodecyl sulphate (SDS), and each
aliquot (10 ml; 30 mg of protein content) of the preparation was
treated with the buffer for SDS-polyacrylamide gel electrophoresis
(PAGE; 10%) under non-reducing conditions as reported earlier
(Okamoto et al, 1997). After electrophoresis, protein was trans-
ferred to ImmobilonTM polyvinylidene difluoride membranes
(Millipore Co., Ltd., Bedford, MA, USA) followed by incubation
with an anti-HO-1 antibody. The protein band that reacted
immunologically with the antibody was visualized by using the
ECLTM system (Amersham), combined with chemiluminescence
detection with Kodak XAR-5 film.
To localize HO-1 in solid tumour tissue (on day 16 after tumour
inoculation), in situ hybridization was performed with use of a
digoxigenin RNA labelling kit (Boehringer Mannheim GmbH,
Mannheim, Germany) according to the method described
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digoxigenin-labelled single-strand RNA probe for HO-1 was
prepared with an HO-1 cDNA fragment (as described above) as a
template. After 10-mm-thick frozen sections of tumour tissue were
prepared, they were fixed for 15 min in 4% paraformaldehyde in
0.1 M phosphate buffer and were rinsed in PBS. The sections were
then treated serially with 0.001% proteinase K, 4% paraformalde-
hyde in PBS, and 0.2 M hydrochloric acid (HCl) and were acetyl-
ated with 0.25% acetic anhydride in 0.1 M triethanolamine,
followed by dehydration through a graded series of ethanol solu-
tions. The sections were then hybridized with either antisense or
sense probes for HO-1 mRNA (10 mg ml–1 for each) in 100 ml of
hybridization solution containing 50% formamide, 0.6 M sodium
chloride, 1 mM EDTA, 10% dextran sulphate, 0.25% SDS, 1 ´
Denhardt’s solution, and yeast tRNA (200 mg ml–1) in 20 mM
Tris–HCl, pH 8.0 at 45°C for 14 h. After hybridization, the
sections were washed with 2 ´ standard saline citrate (SSC)
containing 50% formamide at 45°C for 20 min, digested with
RNAase (5 mg ml–1) at 37°C for 30 min, and washed again with
2 ´ SSC and then 0.5 ´ SSC at 45°C. The hybridized digoxigenin-
labelled RNA was detected colourimetrically by using a nucleic
acid detection kit (Boehringer Mannheim) with a sheep anti-
digoxigenin immunoglobulin [F(ab¢)2] conjugated with alkaline
phosphatase, and nitroblue tetrazolium salt and 5-bromo-4-chloro-
3-indolylphosphate for the colour reaction. The phosphatase
reaction was carried out in a humidified chamber at 37°C for 1 h.
Measurement of HO activity in tumour tissues
The HO activity in the AH136B solid tumour or various organs
such as livers and spleens was assayed as described previously
(Maines and Kappas, 1978). Specifically, the tumour tissues,
which was obtained 16 days after tumour implantation, or the liver
and spleen were homogenized by the Polytron homogenizer in ice-
cold 50 mM potassium phosphate buffer (pH 7.4) containing 2 mM
EDTA, 2 mM PMSF and 10 mg ml–1 of leupeptin. After the
homogenate was centrifuged at 10 000 g for 30 min at 4°C, the
resultant supernatant was used to prepare the microsome fraction
as described above (105 000 g at 4°C). The microsome fraction
was suspended in 0.1 M potassium phosphate buffer (pH 7.4),
followed by sonication for 2 s at 4°C and stored at –70°C until use.
The reaction mixture for the measurement of the HO activity was
composed of 2 mg of microsome protein, cytosol fraction of the rat
liver (3 mg protein) as a source of biliverdin reductase, 33 mM
haemin and 333 mM NADPH in 3 ml of 50 mM potassium phos-
phate buffer (pH 7.4). The reaction was terminated by addition of
0.1 ml of 0.01 M HCl 15 min after incubation of the reaction
mixture. The bilirubin formed in the reaction was extracted with
1 ml of chloroform, and the bilirubin concentration was deter-
mined spectroscopically by measuring the difference in
absorbance between 464 nm and 530 nm by using a molar
extinction coefficient of 40 mM–1 cm–1 (Maines and Kappas, 1978).
Culture of AH136B tumour cells and iNOS and HO-1
induction
AH136B cells obtained from the ascitic form of the tumour were
cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco,
Grand Island, NY, USA) supplemented with non-essential amino
acids (Gibco) and 10% fetal bovine serum in 5% carbon dioxide
95% air at 37°C. Cellular iNOS expression was examined by
reverse transcriptase-polymerase chain reaction (RT-PCR) and
Southern blot analyses. Briefly, total RNA was extracted from a
confluent monolayer of the cells in culture on a 6-well polystyrene
plate (Falcon, Becton Dickinson Labware, Lincoln Park, NJ, USA;
diameter 3.4 cm), and then 3 mg of the RNA were subjected to
RT-PCR and Southern blotting for iNOS mRNA. The reaction
conditions and oligonucleotide primer used for RT-PCR and a
cDNA probe for iNOS are described elsewhere (Doi et al, 1996).
To see whether NO or a related redox form such as nitrosonium
(NO+) induces HO-1 mRNA expression in the tumour cells in
vitro,  S-nitroso-N-acetyl penicillamine (SNAP; Dojindo
Laboratories) was added at various concentrations to the cells
in culture (6-well plate) as just described. After a 5 h incubation
period at 37°C in the carbon dioxide incubator, total RNA was
extracted and 10 mg RNA was used for Northern blotting for HO-1
mRNA in the same manner as for the solid tumour tissues.
Effect of NOS inhibition on HO-1 induction and solid
tumour growth in vivo
To explore the mechanism of HO-1 induction in AH136B solid
tumour, HO-1 mRNA expression with or without NOS inhibitors
was examined by Northern and Western blot analyses.
Specifically, tumour-bearing rats received either L-NAME or SMT
in 0.2 ml saline i.p. at a dose of 3, 10, 30, or 45 mg kg–1 body
weight two times a day for 5 days, beginning 11 days after tumour
implantation. The group given only saline served as a control.
Solid tumour tissues were obtained 1 day after the last injection of
NOS inhibitors, and total RNA was extracted followed by
Northern blotting as described above. The microsome fraction of
the tissue was isolated by ultracentrifugation and was subjected to
Western blotting after SDS-PAGE as noted earlier.
The effect of NOS inhibitors on tumour growth was tested by
treatment of tumour-bearing rats with L-NAME or SMT with the
same protocol as that used for examination of HO-1 expression.
Briefly, after administration of NOS inhibitors, tumour volume
was assessed by measuring both major (a) and minor (b) axes of
the solid tumours with use of a vernier micrometer. Tumour
volume was estimated by use of the formula (p´a ´ b2)/6.
Effect of ischaemic stress on HO-1 expression in
AH136B solid tumours in vivo
HO-1 induction after ischaemic treatment was examined by
Northern blotting and by measuring its enzyme activity. On day
16 after tumour implantation, the solid tumours were resected at
various time points after initiation of surgical occlusion of the iliac
artery, which provides the tumour-feeding artery of the tumour-
implanted side. Ischaemic stress was also caused in solid tumours
by infusion of LipiodolTM containing styrene-co-maleic acid
polymer-conjugated neocarzinostatin (Smancs; 0.1 mg of Smancs
in 1.0 ml of Lipiodol per 5 min) via cannula (PE10; Becton
Dickinson, Sparks, MD, USA) inserted into the feeding artery
(iliac artery) (Yamasaki et al, 1987), and the level of HO-1 mRNA
expression was monitored as in the occlusion model.
Treatment of AH136B solid tumours with an HO
inhibitor in vivo
To examine the role of HO-1 in the solid tumour growth, zinc
protoporphyrin IX (ZnPP) (Wako Pure Chemical, Osaka, Japan)
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tumour-bearing animals. Specifically, 0.1 mg of ZnPP in 0.2 ml of
1.0% DMSO in saline was injected intra-arterial to the solid
tumour via the feeding artery on day 7 after tumour implantation
as just described, and the tumour growth was monitored by
measuring the tumour volume in the same manner as the NOS
inhibition experiment mentioned above. The group given only 200
ml of 1.0% DMSO in saline served as a control without HO
inhibitor treatment.
Statistical analysis
Data are shown as means ± s.e.m. Statistical difference was
analysed by the two-tailed unpaired t-test. A P-value of < 0.05 was
considered statistically significant.
RESULTS
Excessive production of NO was demonstrated in AH136B solid
tumours in rats by ESR spectroscopy: a significant ESR signal of
the NO-(DTCS)2-Fe2+ adduct was identified (Figure 1). In
contrast, only a negligible ESR signal of the NO adduct was
observed when animals were given L-NAME or SMT (Figure 1).
Because a strong, steady level of induction of iNOS mRNA was
observed, we then examined the localization of iNOS in the
tumour tissue.
As demonstrated in Figure 2A, an immunohistochemical study
revealed that iNOS is expressed only by cells infiltrating the inter-
stitial space, but not by tumour cells. TRPM-3-positive monocyte-
derived macrophages were also found to infiltrate the interstitial
space of the solid tumour (Figure 2B). The location of iNOS-
positive cells appears to be almost the same as that of TRPM-3-
positive cells in the tumour tissue. Therefore, iNOS-positive cells
were considered to be interstitial infiltrating macrophages rather
than AH136B tumour cells. No appreciable immunostaining was
observed by the control staining with non-immunized serum or
PBS instead of the primary antibodies (anti-iNOS antibody or
TRPM-3) (not shown). This result also suggests that monocyte-
derived activated macrophages infiltrating in tumour seem to be
primarily responsible for overproduction of NO. The lack of iNOS
expression in AH136B tumour cells was further substantiated
because no appreciable iNOS mRNA expression was observed
with AH136B cells in culture by using RT-PCR (Southern blot-
ting) and Northern blotting (data not shown).
Strong HO-1 expression was observed in the solid tumour as
assessed by both Northern and Western blot analyses, and by HO
activity measurement as well (Figure 3 A–C). HO-1 mRNA
expression in the solid tumour in vivo was higher than that in the
tumour cells in vitro (Figure 3A). The level of HO-1 induction in
the solid tumours was comparable to that in the spleen, which is
known to express HO-1 constitutively under physiological condi-
tions (Figure 3 B, C). In contrast to iNOS, HO-1 was observed
only in tumour cells of the solid tumour tissue as identified by in
situ hybridization with an HO-1 RNA probe (Figure 4).
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Figure 1 ESR spectra obtained with AH136B solid tumour tissue. Thirty minutes before the tissue was obtained, a DTCS-Fe2+ complex (180–40 mg kg–1) was
given s.c. to the rats treated (B, C) or untreated (A) with NOS inhibitors (50 mg kg–1, i.p.). All ESR measurements were performed at 110 K. See text for detailsTo determine the effect of NO in induction of HO-1, AH136B
cells in culture were analysed for expression of HO-1 mRNA after
treatment with SNAP in vitro. As shown in Figure 5, induction of
HO-1 mRNA was clearly increased in a dose-dependent manner
when SNAP was added to the cell culture system. This result
indicates that NO or its related redox isoform, NO+, has a potent
HO-1-inducing potential in AH136B tumour cells.
The level of HO-1 mRNA in solid tumours in vivo decreased
significantly after treatment with low doses (6 and 20 mg kg–1) of
NOS inhibitors such as L-NAME and SMT. However, as the NOS
inhibitor dose increased up to 90 mg kg–1 day–1, HO-1 mRNA
expression gradually recovered to a level similar to that of the
solid tumour without treatment (Figure 6). Similar results for the
effect of NOS inhibition on HO-1 protein expression were
obtained by Western blotting for rat HO-1 (data not shown). The
efficacy of NOS inhibition by L-NAME and SMT was tested by an
ESR study, and treatment with either L-NAME or SMT abrogated
NO production completely in solid tumour tissues as just
mentioned (Figure 1 B, C).
To explain the inconsistency in the effect of NO on HO-1 induc-
tion in vitro and in vivo, we examined the effect of ischaemic
stress on the solid tumours in rats. Ischaemia caused by occlusion
of the tumour-feeding artery and by infusion of Smancs/Lipiodol
resulted in strong up-regulation of HO-1 mRNA expression
(Figure 7A and B). Although there was about a 24-h gap between
HO-1 mRNA up-regulation and HO activity induction, the HO
activity in the solid tumour was apparently enhanced by the
ischaemic stress (Figure 7C).
Moreover, when tumour growth in vivo was investigated with
the use of NOS inhibitors, moderate retardation of tumour growth
was observed with both L-NAME and SMT (Figure 8), but this
effect was not as remarkable as their strong inhibition of NO
biosynthesis, as evidenced by ESR spectroscopy (Figure 1 B, C).
In contrast, the treatment of HO inhibitor (ZnPP), which signifi-
cantly inhibited HO activity in the solid tumour, showed a great
suppression of the tumour growth in vivo (P < 0.01) (Figure 9). In
a separate experiment, NO production in the solid tumour with or
without ZnPP treatment was investigated by using ESR spec-
troscopy as just described. ZnPP administered intraarterially,
however, did not affect NO biosynthesis by iNOS expressed in the
tumour tissue (data not shown).
DISCUSSION
In our earlier study, excessive production of NO as assessed by
ESR spectroscopy correlated well with the rate of growth of
AH136B solid tumours in rats (Doi et al, 1996). The present study
was performed to further explore this observation and to clarify the
role of NO in solid tumour biology, by focusing on the induction
and function of HO-1 in AH136B solid tumours.
Rapid tumour growth is sustained by a number of factors
derived from tumour cells or a host’s tissue in solid tumours
(Matsumura et al, 1988; Vaupel et al, 1989; Maeda et al, 1994;
Nakano et al, 1996; Suzuki et al, 1996; Wu et al, 1998).
Maintenance of regional blood flow in solid tumour tissues
appears to be most important for tumour cell growth, for a suffi-
cient supply of molecular oxygen and various nutrients. It is now
well known that NO released from vascular endothelial cells plays
an important physiological role in regulation of blood flow in
systemic circulation via its potent vasodilating action (Moncada
NOS and HO in tumour growth 1949
British Journal of Cancer (1999) 80(12), 1945–1954 © 1999 Cancer Research Campaign
AB
Figure 2 Immunohistochemistry with antibodies against iNOS and monocyte-derived macrophages (TRPM-3). The localization of iNOS expression was
examined in the AH136B solid tumour obtained 16 days after implantation (A). With a sequential section of the tumour tissue shown in (A), immunostaining was
performed with TRPM-3 antibody specific against monocyte-derived exudate macrophages (B). Arrows in (A) and (B) indicate the cells showing apparently
consistent localization of the stainings with both anti-iNOS antibody and TRPM-3. Magnification ´ 170. See text for detailsand Higgs, 1993). Growth of solid tumour, therefore, may be
sustained by increased blood flow mediated by prolonged and
excessive production of NO.
Our previous experiment showed that enhanced vascular
permeability to tumour tissues was mediated by NO (Maeda et al,
1994; Wu et al, 1998). Leibovich et al (1994) reported that an
L-arginine-dependent NO pathway mediates angiogenic activity.
Interestingly, Ziche et al (1997) recently reported that vascular
endothelial growth factor, VEGF (also called vascular perme-
ability factor, VPF), induces angiogenesis via formation of NO.
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Figure 3 Northern blot (A) and Western blot (B) analyses for HO-1 expression and HO activity (C) in AH136B tumours. Northern hybridization was performed
with AH136B tumours obtained in vitro and in vivo with use of a cDNA probe for rat liver HO-1 (A). The expression of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA in each tissue was determined as for HO-1, as shown in the lower panel. Western blotting was done by using a specific
antibody for rat HO-1 with AH136B solid tumour tissue, liver, and spleen (B). The HO activity was assayed spectroscopically based on the bilirubin formation
from haem in the reaction mixture of the microsome fraction of various tissues in the presence of the rat liver cytosol protein as a source of biliverdin reductase
(C). Data are shown as means ± s.e.m. (n = 4; *P < 0.05). Note that the HO activity in each tissue determined was strongly inhibited by addition of
30 mM ZnPP mg–1 of microsome protein to the assay mixture. The microsome fraction of the tissue was isolated by ultracentrifugation and was subjected to
Western blot analysis after SDS-PAGE and to the measurement for HO activity. See text for details.Angiogenesis leading to hypervascularization is often observed
during rapid tumour growth. Consequently, it is plausible that
the angiogenic potential as well as the vascular permeability
enhancing effect of NO may facilitate rapid growth of solid
tumours, which have great demands for various nutrient factors. A
similar beneficial effect of NO on tumour growth was clearly
demonstrated recently in tumour-bearing mice, in which human
adenocarcinoma cells, which overexpressed iNOS, were
implanted (Jenkins et al, 1995). A promoting effect of NO on
tumour progression and metastasis is also suggested by Lala and
Orucevic (1998). These results are supported by the finding that
inhibition of NO synthesis by an NOS inhibitor given systemically
reduced tumour growth in mice (Andrade et al, 1992; Thomsen et
al, 1997; our present results).
In contrast, it has been reported that NO is an effector molecule
in macrophage-mediated cytotoxicity (Hibbs et al, 1988; Bastian
et al, 1994; Lepoivre et al, 1994). We showed in the present exper-
iment that the tumour-infiltrating activated macrophage seems to
be a major contributor to overproduction of NO in the solid
tumour. This observation appears to conflict with the above-
mentioned result. To solve these contradictory issues, we probed
the mechanism of efficient tumour growth in the presence of an
excess amount of NO in the solid tumours.
In this context, Lancaster’s group reported that pretreatment of
rat hepatocytes with a low dose of NO donor confers resistance to
oxidative damage of the cells, through induction of HO-1 (Kim et
al, 1995a). In their report, it is also demonstrated that HO-1 induc-
tion protected the cells from NO-mediated cytotoxicity. HO-1,
which catalyses the conversion of haem to biliverdin and CO, has
been shown to be constitutively expressed in the liver and spleen
and in some tumour cells (Tenhunen et al, 1968; Shibahara et al,
NOS and HO in tumour growth 1951
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AB
Figure 4 In situ hybridization for HO-1 expression in AH136B solid tumour. Sections of solid tumour were hybridized with antisense (A) or sense (B) RNA
probes for HO-1 labelled with digoxigenin. AH136B cells are positively stained with the antisense probe for HO-1. Magnification ´ 130. See text for details
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Figure 5 Northern blot analysis for HO-1 mRNA expression in AH136B
tumour cells in culture treated with SNAP. After treatment of cells with
various concentrations of SNAP for 5 h, Northern blotting for HO-1 mRNA
expression was perfomed in the same manner as described in Figure 3. In
the lower panel, the HO-1 mRNA signals were quantified by densitometric
analysis, after normalization with GAPDH mRNA signals as a standard
mRNA expression, using a Macintosh computer with an Image Scanner
(GT6500, Epson Co., Ltd, Tokyo, Japan) and the public domain NIH Image
Program. See text for details1952 K Doi et al
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Figure 6 Northern blot analysis for HO-1 mRNA expression in AH136B solid tumours treated with NOS inhibitors. Tumour-bearing rats received either L-
NAME or SMT i.p. at a dose of 3, 10, 30, or 45 mg kg–1 two times a day for 5 days, starting 11 days after tumour implantation. Northern blotting for HO-1 mRNA
expression was performed in the same manner as described in Figure 3. In the lower panels, quantitative image analysis for HO-1 mRNA was performed in a
same manner as in Figure 5. See text for details
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Figure 7 HO-1 mRNA expression in AH136B solid tumours under ischaemic conditions caused by occlusion of the feeding artery (A) or embolization with a
Smancs-Lipiodol emulsion (0.1 mg of Smancs in 0.1 ml of Lipiodol) (B). Lower panels in (A) and (B) show the relative signal intensities of HO-1 mRNA
quantified similar to Figure 5. (C) Induction of HO activity in the solid tumour was also examined after occlusion of the feeding artery in the same manner as in
(A). Data are expressed means ± s.e.m. (n = 4; *P < 0.05). Northern blotting was carried out with the solid tumour obtained at various time points after occlusion
of the feeding artery or treatment with Smancs-Lipiodol. In a control study (sham operation), HO-1 mRNA expression was examined after laparotomy without
occlusion of the feeding artery. See text for details
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sham op.
sham op.1985; Lee and Ho, 1994; Goldman et al, 1996; Hara et al, 1996;
Maines, 1997). Furthermore, HO-1 is readily induced by haem
compounds, heavy metals, UV irradiation and a variety of oxida-
tive stresses (Maines and Kappas, 1974; Kim et al, 1995a, 1995b;
Maines, 1997). One possible mechanism of the protective effect of
HO-1 induction is thought to be the antioxidant action of bilirubin
(Stocker et al, 1987; Kim et al, 1995a, 1995b), which is generated
by reduction of biliverdin, a product of the enzymatic reaction of
HO using haem as a substrate. In addition, ferritin, whose expres-
sion was triggered by iron release during haem breakdown cata-
lysed by HO-1, has been proposed to protect against oxidative
stress by sequestering iron (Kim et al, 1995b). On the basis of
these findings related to the role of HO-1 induction in cellular
defense mechanisms, induction of HO-1 may benefit the tumour
cells themselves.
In fact, in our present experiment with a solid tumour model in
rats, HO-1 was constantly up-regulated. The level of HO-1 mRNA
expression was apparently enhanced in AH136B tumour cells in
culture by treatment with an NO (NO+) donor. Regulation of HO-1
expression by NO was also verified in AH136B tumour-bearing
rats in vivo, as revealed by suppression of HO-1 induction by NOS
inhibitor treatment of the animals. However, reduction in HO-1
expression was only marginal when higher doses (more than
60 mg kg–1) of NOS inhibitor were administered, in which NO
biosynthesis will be completely inhibited in AH136B solid tumour
tissues. This bell shape suppression of HO-1 expression by NOS
inhibitors in the solid tumour may be explained by the fact that
ischaemic or hypoxic stress is also a potent inducer of HO-1 in
AH136B solid tumour in rats, as seen in Figure 7. Specifically, a
complete inhibition of NO synthesis by NOS inhibitors led to
profound reduction of tumour blood flow and thus resulted in an
ischaemic insult to AH136B solid tumours, which may then
trigger up-regulation of HO-1 in the tissue even in the absence of
stimulation with NO. In this context, it is reported that hypoxia is
indeed caused by an NOS inhibitor (Nw-nitro-L-arginine) in
experimental murine tumours (Wood et al, 1994).
In addition, we observed only moderate suppression of tumour
growth in vivo with NOS inhibitor treatment. In view of our
present finding that not only NO but also ischaemic stimuli can be
the major inducers of HO-1 expression in solid tumours, it may be
that HO-1 has a compensatory function to sustain effective tumour
growth even after suppression of the potent vasoactive NO.
Moreover, it is of considerable importance that intra-arterial
administration of the HO inhibitor ZnPP strongly suppressed the
AH136B tumour growth in vivo (Figure 9). This result supports
the above notion that compensatory HO-1 induction in the solid
tumour may be advantageous for tumour cell growth.
In conclusion, our current study indicates that HO-1 expression
in solid tumour appears to be regulated by NO and ischaemic
stress, which should often occur in tumour tissue during rapid
tumour growth in vivo. The up-regulation of HO-1 may have
protective and beneficial effects for tumour cells against anti-
tumour actions of the host as well as many anticancer agents.
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Figure 8 Effect of HO inhibitor treatment on tumour growth. Tumour-
bearing rats received either L-NAME or SMT i.p. at a dose of 3, 10, 30, or
45 mg kg–1 two times a day for 5 days, starting 11 days after tumour
implantation. The rate of gain in tumour volume was assessed by comparing
sizes of both major (a) and minor (b) axes of the solid tumours at 11 and
16 days after tumour cell implantation. The group given only saline served as
control. Tumour volumes was estimated by use of the formula (π 3 a 3 b2)/6.
Data are shown as means ± s.e.m. (n = 8);  asterisks show significant
differences versus the control group by the t-test for unpaired data
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Figure 9 Effect of HO inhibitor treatment on tumour growth. ZnPP (0.1 mg)
in 0.2 ml saline (1.0% DMSO) was administered to the solid tumour via the
feeding artery (iliac artery) involving laparotomy at 7 days after tumour
implantation. The tumour growth was assessed in the same manner as
described in Figure 8. The control group received only 0.2 ml of 1.0% DMSO
in saline. Data are shown as means ± s.e.m. (n = 4); asterisks show
significant differences versus the control group by the t-test for unpaired data
(*P < 0.05; **P < 0.01). The inset shows the HO activity in the solid tumour,
which was assessed before (7 days after tumour inoculation) and after ZnPP
treatment (n = 4 except that n = 1 for day 7 after ZnPP treatment)REFERENCES
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